Kelly Cloud describes the assets, infrastructure, and incentives that the Dallas area offers life sciences companies.

BioNTX CEO Kathleen Otto gives us a summary of the biotech activity in North Texas.

Alex Thompson gives a deep dive into the I&I space and discusses Apogee, Aeglea, argenx, Immunovant, Aclaris, Morphic, and Ventyx.

Larry Tiffany describes how GenrAb is leveraging neurodegenerative stress and immunoogenetic models from UTSW for antibody discovery.

Marty Driscoll describes how OncoNano is utilizing a tumor's acidic environment to develop therapies and imaging agents.

Vinny Jindal describes Secretome's approach to using neonatal cardiac progenitor cells.

Dan Siegwart describes what goes into getting LNPs to places in the body beyond the liver, and how he has co-founded ReCode Therapeutics.

Claire Aldridge explains how Form Bio was derived from the work that Colossal Bio was doing in Texas.

Dr. Olson describes work that has come out of his lab that aims to help diseases such as muscular dystrophy and hypertrophic cardiomyopathy.

David Greenberg describes Solenic Medical's non-pharmaceutical solution to implant infections.

Nicole Small describes the investments in infrastructure that are being made to grow entrepreneurs’ ability to keep science at home in DFW.

Elazer Edelman explains how MIT acts as a bridge between the development of technology and the introduction of technology.

Floris Engelhardt describes how Kano is trying to use circular single-stranded DNA to correct gene length stretches of the genome.

Andrey Zarur says that GreenLight is the largest manufacturer of RNA in the wold.

Stella Paffenholz says areas like gene editing, radiopharmaceuticals, and innovative small molecules make this an exciting time.

Imran Eba explains the idea of aiming to treating any disease by stimulating or blocking nerve signals, an investment focus of his firm.

Steve Favaloro explains why the industry is seeing shortages and what is being done by companies to boost supply.

Arjun Goyal describes how firms are trying to navigate both the private and public markets in biotech today.

Bill Maughan discusses Nkarta, ESMO news on Bicycle, BioNTech, Olema, and Xencor, and comments on iPSC companies, Immmunocore, and more.

Dr. Bertozzi describes how types of cell surface glycans play a role in immune modulation and how Palleon is trying to drug them.